United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Nations Financial Group Inc. IA ADV

Nations Financial Group Inc. IA ADV lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,904 shares of the biotechnology company’s stock after buying an additional 136 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in United Therapeutics were worth $1,041,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in UTHR. ClariVest Asset Management LLC increased its holdings in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics in the second quarter worth $30,000. Innealta Capital LLC purchased a new position in shares of United Therapeutics during the second quarter worth $33,000. USA Financial Formulas acquired a new position in United Therapeutics during the third quarter valued at $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics in the third quarter valued at $82,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on UTHR. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company boosted their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, The Goldman Sachs Group raised their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Stock Up 0.1 %

Shares of UTHR opened at $400.87 on Wednesday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The stock has a market cap of $17.90 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56. The firm’s fifty day moving average is $360.91 and its two-hundred day moving average is $325.71.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.38 earnings per share. As a group, research analysts anticipate that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 113,396 shares of company stock worth $42,175,418. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.